

From: Jeffrey Epstein <jeevacation@gmail.com>
To: Erdoes, Mary E <[REDACTED]>
CC: Jes Staley <[REDACTED]>
Sent: 8/17/2011 1:17:45 AM
Subject: Re: Questions

I will get more detailed answers but for now 1. not sure what you mean by R & d ? . no input from the foundation into investments.. donors can choose from either a custom made portfolio. . or a choice of silos, and be able to switch . (mutual fund concept) 2. mostly initially american. initially , however we should be ready with an offshore arm. - especailly for vaccines. 3. The donor advised limits influence re grants. but allows great fliexibility on investments. . anonymoity is varied , according to both gifts to and gifts from 4. pooled is not really necessary but would be availble for those that preferred it. 5. billions of dollars. the first two years. tens of billions by year 4. timelimne depends only on jpm ability to organize, legal, structure internet presence, staffing. etc 5. exists in perpetuity, with succession controls. 6. there will be acess to the current foundations pools of targets. but would be looking for both new opportunities with metrics for success.

On Wed, Aug 17, 2011 at 1:43 AM, Erdoes, Mary E <[REDACTED]> wrote:
Here are some questions we have in advance of the meeting, to the extent we can find the answers:

What role will the Gates foundation play vis-a-vis other donors with respect to marketing, sharing of R&D, grant making and investments?

What is the profile of the potential donors, including residence & tax status? What level of influence will they want to maintain across investments and grant making? How important is anonymity?

Is pooling of investments and pooled grant making a core feature of the offering?

What is the potential funding amount and what is the anticipated funding rate?

What is the timeline for launch? Is the objective to create a vehicle to exist in perpetuity or is it a thematic spend-down over time?

Are there specific themes and charities identified for grant making or is there a broad scope of charitable targets?

These are all generic questions from the team, but to the extent we can get any guidance on some of the direction, it would be very helpful before the 31st.

From Maroon Bells,
Mary

This email is confidential and subject to important disclaimers and conditions including on offers for the purchase or sale of securities, accuracy and completeness of information, viruses, confidentiality, legal privilege, and legal entity disclaimers, available at <http://www.jpmorgan.com/pages/disclosures/email>.

--

The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of Jeffrey Epstein

Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to jeevacation@gmail.com, and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved

SDNY_GM_00078521

Confidential Treatment Requested by JPMorgan Chase

JPM-SDNY-00001648

EFTA_00188988

EFTA01256270